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Opioid neurotransmission has a key role in mediating reward-related behaviours. Opioid
receptor (OR) antagonists, such as naltrexone (NTX), can attenuate the behaviour-reinforcing
effects of primary (food) and secondary rewards. GSK1521498 is a novel OR ligand, which
behaves as an inverse agonist at the l-OR sub-type. In a sample of healthy volunteers, we used
[11C]-carfentanil positron emission tomography to measure the OR occupancy and functional
magnetic resonance imaging (fMRI) to measure activation of brain reward centres by palatable
food stimuli before and after single oral doses of GSK1521498 (range, 0.4–100mg) or NTX
(range, 2–50mg). GSK1521498 had high affinity for human brain ORs (GSK1521498 effective
concentration 50=7.10ngml1) and there was a direct relationship between receptor
occupancy (RO) and plasma concentrations of GSK1521498. However, for both NTX and its
principal active metabolite in humans, 6-b-NTX, this relationship was indirect. GSK1521498,
but not NTX, significantly attenuated the fMRI activation of the amygdala by a palatable food
stimulus. We thus have shown how the pharmacological properties of OR antagonists can be
characterised directly in humans by a novel integration of molecular and functional
neuroimaging techniques. GSK1521498 was differentiated from NTX in terms of its
pharmacokinetics, target affinity, plasma concentration–RO relationships and pharmacody-
namic effects on food reward processing in the brain. Pharmacological differentiation of these
molecules suggests that they may have different therapeutic profiles for treatment of
overeating and other disorders of compulsive consumption.
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Introduction
The endogenous opioid neurotransmitter system
comprises a number of peptides (including b-endor-
phins, enkephalins and dynorphins) and three major
opioid receptor (OR) sub-types: m, d and k.1–3 OR
agonists increase, whereas antagonists decrease,
feeding and other rewarding behaviours in animal
models.4–9 Agonism at the m-OR sub-type seems to be
particularly effective in enhancing the hedonic and
consummatory eating behaviours,6,10–12 as demon-
strated by greater intake of energy-dense foods. This
effect is blocked by OR antagonists.13,14 Direct infu-
sion of m-OR agonists has been used to localise effects
on eating behaviour to the nucleus accumbens in
rats.10–13,15,16 The basal nucleus of the amygdala
provides a major input to the nucleus accumbens,17
amplifying the hedonic value of palatable food
and its motivational influence on goal-directed
behaviours.18–22
Opioid signalling in humans has been implicated in
behaviours reinforced by primary rewards, especially
fatty or sugary foods, or secondary rewards, such as
self-administered drugs. Acute administration of
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drugs broadly classified as OR antagonists (for
example, naltrexone (NTX)) moderately reduces
short-term food intake23 and affective or subjective
pleasantness of palatable foods in healthy
subjects;23–26 and reduces food or drug intake in
short-term animal and experimental medicine models
of obesity, binge eating, alcohol and drug dependence
syndromes.23–28 NTX is licensed for treatment of
alcohol and opiate addiction.
GSK1521498 is a novel OR ligand with a high
degree of selectivity for the m-OR sub-type in binding
studies (Table 1). It has antagonist effects at the m-OR
receptor, or inverse agonist properties under condi-
tions of constitutive receptor activity. In a first-in-
human acute dose escalation study, single doses were
safe and well tolerated up to a maximum tolerated
dose of 100mg.33 A single 25mg dose of GSK1521498
was associated with reduced pleasurable response to,
and reduced consumption of, high fat/high sugar
snack items in an experimental model of overeating
behaviour in overweight volunteers.33
Here we used neuroimaging to investigate m-OR
occupancy and effects on brain function of single
doses of NTX and GSK1521498 in healthy volunteers.
We used positron emission tomography (PET) with
[11C]-carfentanil to measure m-OR occupancy over a
range of doses and plasma concentrations of both
drugs. In the same scanning sessions, we also used
functional magnetic resonance imaging (fMRI) to
measure food reward-related activation of theoreti-
cally predicted brain regions, including amygdala and
striatum.34–39 We compared the two drugs in terms of
their pharmacokinetics, target occupancy and prox-
imal functional efficacy.
Materials and methods
Participants
In all, 26 healthy male volunteers (25–60 years old,
body weight > 50kg and body mass index 19–
30 kgm2) were recruited from the London area by a
research organisation, Hammersmith Medical Re-
search, contracted by the GSK Clinical Imaging
Centre, London. All subjects satisfied eligibility
criteria and passed a medical screen for fitness to
participate (see Supplementary Information for de-
tails), and provided informed consent for participa-
tion in writing.
Study design
This was an open label study, with participants
assigned to either GSK1521498 or NTX treatment
Table 1 Opioid receptor sub-type binding affinities and plasma pharmacokinetic parameters for naltrexone, 6-b-naltrexol and
GSK1521498
OR sub-type affinity (nM)
Naltrexone 6-b-Naltrexol GSK1521498
m-OR 0.5 (ref. 29) 1.4 (ref. 29)
2.1 (ref. 30)
0.31 (ref. 31) 0.74 (ref. 31)
4.7a 1.5a
k-OR 1.0 (ref. 29) 2.0 (ref. 29)
7.4 (ref. 30)
20.0a 20.4a
d-OR 7.0 (ref. 29) 29 (ref. 29)
213 (ref. 30)
42a 30.2a
Pharmacokinetic parameters (minimum-maximum)
AUC (0, t), ng h1ml1 0.06–23.6 14.1–618 20.4–10 422
AUC (0, t), nMh1 0.18–69.1 41–1800 50.7–25842
Cmax, ngml
1 0.046–9.01 1.2–93 1.5–929
Cmax, nM 0.13–26.4 3.5–271 3.8–2308
Exposures during PET scanning, ngml1 0.013–1.87 0.32–37.8 1.1–286
Exposures during PET scanning, nM 0.04–5.5 0.94–110 2.7–711
Tmax, h 0.5–2 0.5–2 1–4
T1/2, h 4 (ref. 32) 13 (ref. 32) 20–24 (ref. 33)
Abbreviations: AUC, area under curve; OR, opioid receptor; PET, positron emission tomography.
aGlaxoSmithKline internal data.
While data from different studies can be used to compare drug selectivities at the OR sub-types, comparison of absolute
affinity values from different studies should be carried out cautiously because of the differences in the system examined and
assay conditions. Affinity data were estimated from pKi of displacement of appropriate radio ligands from human ORs
expressed in a cell system,29,30 or from monkey cortical homogenates.31 The GlaxoSmithKline internal data were estimated
from a functional (f)pKi in a [35S]GTPgS assay on human OR expressed in CHO-E1A cells.
pKi = base 10 logarithm of the drug concentration that gives 50% of maximum receptor binding.
Pharmacological differentiation of opioid receptor antagonists
EA Rabiner et al
827
Molecular Psychiatry
groups at enrolment. Each participant underwent up
to three [11C]-carfentanil PET scans and two fMRI
examinations: one [11C]-carfentanil PET scan and one
fMRI scan at baseline (before dosing) and up to two
PET scans and one fMRI scan following oral admin-
istration of a single dose of GSK1521498 or NTX. Two
participants opted to withdraw from the study
following completion of the baseline scanning ses-
sion: the complete PET dataset available for analysis
therefore comprised 24 participants.
The administered doses of GSK1521498 or NTX
were chosen adaptively to optimise the estimation of
the dose–occupancy relationship for each drug on the
basis of data acquired from the preceding examina-
tions in the study.40 The administered dose range was
0.4–100mg for GSK1521498, and 2–50mg for NTX.
The maximum doses administered were equal to the
maximum tolerated dose of GSK1521498 determined
in the first-in-human study33 and the standard
clinical dose of NTX used for alcohol dependence.41
The times and doses of the two post-dose [11C]-
carfentanil PET scans were chosen adaptively for each
subject to optimise estimation of the relationship
between plasma concentration and RO.40 Post-dose
[11C]-carfentanil PET scans were acquired at 3–36h
after the administration of GSK1521498 and at 3–88h
after the administration of NTX. Post-dose fMRI scans
were acquired within 60min of the first post-dose
PET scan.
Sampling and analysis of drug plasma concentrations
Venous blood samples were collected at regular
intervals throughout the scanning sessions. High-
performance liquid chromatography/mass spectrome-
try/mass spectrometry was used to estimate the
plasma concentrations of GSK1521498, NTX, and
the major metabolite of NTX, 6-b-naltrexol (6-b-NTX;
see Supplementary Information for assay details).
Drug plasma concentration at the start of each PET
scan was used to model the relationship between drug
concentrations and m-OR occupancies.
[11C]-carfentanil PET data acquisition and
pre-processing
Carfentanil (methyl 1-(2-phenylethyl)-4-(phenyl
(propanoyl)amino)-4-piperidinecarboxylate 3S, 5S;
Advanced Biochemical Compounds, Radeberg,
Germany), a potent selective m-OR agonist, was labelled
with carbon-11 using a modification of a previously
described method42 implemented using a semiauto-
mated Modular Lab Multifunctional Synthetic Module
(Eckert & Ziegler, Berlin, Germany). The final product
was reformulated in sterile 0.9% saline containing
B10% ethanol (v/v) and satisfied quality control
criteria for specific activity and purity before being
injected intravenously as a slow bolus over B30 s.
PET scanning was conducted in three-dimensional
mode using a Siemens Biograph 6 Hi-Rez PET-CT for
the NTX group and a Siemens Biograph 6 TruePoint
PET-CT for the GSK1521498 group (Siemens
Healthcare, Erlangen, Germany). A low-dose CT scan
was acquired for attenuation correction before the
administration of the radiotracer. Dynamic PET data
were acquired for 90min after [11C]-carfentanil injec-
tion, binned into 26 frames (durations: 815 s,
3 60 s, 52min, 55min and 5 10min), recon-
structed using fourier re-binning and a two-dimen-
sional-filtered back projection algorithm and then
smoothed with a two-dimensional Gaussian filter
(5mm at full width half maximum).
PET data analysis
Dynamic PET images were registered to each partici-
pant’s T1-weighted anatomical MRI volume and
corrected for head motion using SPM5 software
(Wellcome Trust Centre for Neuroimaging, http://
www.fil.ion.ucl.ac.uk/spm). Pre-selected regions of
interests (ROIs; amygdala, caudate, putamen, thala-
mus, cerebellum, frontal and occipital cortices) were
defined bilaterally on the T1-weighted anatomical
volume using an in-house atlas43 and applied to the
dynamic PET data to generate regional time-activity
curves (Figure 1).
The [11C]-carfentanil-specific binding was quanti-
fied as binding potential relative to the non-displace-
able compartment (BPND
44)
BPND ¼ fNDBavail
KD
ð1Þ
where fND is the free fraction of the radioligand in the
brain, KD is the affinity of [
11C]-carfentanil, and Bavail
is the density of the available m-ORs. Regional [11C]-
carfentanil BPND was estimated using a reference
tissue model45 with the occipital cortex as the
reference region. Drug related occupancy of the
m-OR was quantified as a reduction of [11C]-carfentanil
BPND
OccupancyDrug ¼
BPBaselineND  BPDrugND
BPBaselineND
ð2Þ
The affinity constant for each drug at the m-OR
(effective concentration 50 (EC50)) was estimated by
fitting the plasma concentration measured at the start
of the PET scan, CDrug
P , to the estimated occupancy:
OccupancyDrug ¼
CPDrug
CPDrug þ EC50
ð3Þ
fMRI: food stimuli and activation paradigm
Food stimuli for the fMRI task were delivered
orally in the scanner and, for different trials, were
either 0.5ml of a highly palatable commercially
available drink (marketed in the United Kingdom as
a ‘smoothie’), 0.5ml of a neutral solution (25mM KCL
and 2.5mM NaHCO3 in water) or 1.0ml of purified
water. Although data from trials with the neutral
solution will not be reported here, the full activation
paradigm consisted of 16 palatable drink and
16 neutral solution trials, presented in rando-
mised order. Purified water was delivered after each
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stimulus trial; we allowed a slightly greater volume of
purified water (1ml) to wash away residual traces of
the flavoured stimuli (0.5ml) between trials. To
minimise head movements during delivery of the
stimuli, participants were instructed to refrain from
swallowing until a cue was presented 5 s later.
fMRI: data acquisition
T2*-weighted, dual echo, echo-planar images sensi-
tive to blood oxygenation level-dependent (BOLD)
contrast were acquired continuously on a 3T Siemens
Tim Trio scanner with a 32-channel head coil
(Siemens Healthcare). Each scan session consisted of
390 volumes of a 38-slice acquisition, angled B301
coronally to the anterior–posterior commissural plane
to minimise signal dropout in orbitofrontal and
medial temporal regions (relaxation time=2100ms;
dual echo time (TEs) = 13 and 31ms; flip angle = 801,
matrix size = 6464, and field of view=225
225mm for voxel size of 3.03.0 3.0mm). High-
resolution T1-weighted anatomical scans (ADNI
MPRAGE (Alzheimer’s disease neuroimaging initia-
tive magnetization-prepared rapid gradient echo)46)
were acquired with whole-brain coverage (208 slices)
for each participant to facilitate fMRI and PET image
co-registration and PET ROI definition (relaxation
time=3000ms, TE=3.66ms, flip angle = 91, voxel
size = 1mm3).
fMRI: data analysis
fMRI data were corrected for head motion, high-pass
filtered and spatially smoothed using FSL software:
http://www.fmrib.ox.ac.uk/fsl (see Supplementary
Information for details). We estimated the difference
in regional mean BOLD signal intensity between
periods of palatable stimulus delivery and periods
of purified water delivery, at each of nine ROIs
bilaterally (as defined a priori in the protocol at
http://clinicaltrials.gov). These estimates were then
averaged over right and left homologous regions of
amygdala, caudate, globus pallidus, hippocampus,
insula, nucleus accumbens, orbitofrontal cortex,
thalamus and putamen. In each treatment group, we
tested the null hypothesis that the within-subject
difference between baseline (pre-dose) and post-dose
scans in regional BOLD response to palatable stimuli
versus purified water was zero: (post-dose BOLD
response to palatable trials)(pre-dose BOLD re-
sponse to palatable trials) =D-BOLD=0. To control
for between-subject variability in m-OR occupancy (by
either drug) and for variability in BOLD activation at
baseline, we also tested D-BOLD in each ROI using a
linear model including baseline BOLD activation and
RO as covariates. To control for multiple comparisons
in these planned regional analyses of treatment-related
differences in brain activation, the threshold for signi-
ficance was Bonferroni corrected at P<0.05/9=0.0055.
We also tested the null hypothesis that there is no
difference in D-BOLD between drugs (D-BOLDGSK1521498
=D-BOLDNTX), and between-drug comparisons were
controlled for baseline activation and RO.
We also conducted exploratory voxel-level analyses
of the fMRI data. Combining data from both treatment
groups, we used the general linear model to estimate
10−1 100 101 102
0
20
40
60
80
100
Dose (mg)
O
cc
up
an
cy
 (%
)
10−1 100 101 102
0
20
40
60
80
100
Dose (mg)
O
cc
up
an
cy
 (%
)
0 10 20 30 40 50 60 70 80 90
0
1
2
3
4
5
6
7
Time (min)
R
O
I a
ct
iv
ity
 (%
 in
jec
ted
 do
se
pe
r l
itr
e)
 
ba
dc
VST
Occipital Lobe
Figure 1 Opioid receptor binding by [11C]-carfentanil and its displacement by naltrexone and GSK1521498. (a) Slices of an
individual positron emission tomography scan demonstrating high binding in sub-cortical nuclei at baseline, which was
reduced following administration of GSK1521498 50mg. (b) Time–activity curves for ventral striatum (VST, red lines) and for
occipital cortex (black lines) at baseline (solid lines) and after a dose of GSK1521498 50mg (broken lines). Dose–occupancy
curves for (c) GSK1521498 and (d) naltrexone, estimated from scans acquired at < 8h after dosing. Vertical line indicates
effective dose 50 and the dotted lines are its 95% confidence interval.
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activation by palatable stimuli versus purified water.
This contrast was tested by permutation at the level of
spatially contiguous supra-threshold voxel clusters,
controlling the family-wise probability of type 1 error
at P<0.05 to generate a map of the brain systems
activated by food reward. Within this reward system,
we separately tested at each voxel the hypotheses that
D-BOLD=0 for GSK1521498 and for NTX, and that
D-BOLDGSK1521498 =D-BOLDNTX. These exploratory
whole-brain analyses are reported at a cluster-wise
level of type 1 error P<0.05, uncorrected for multiple
comparisons.
Results
Evaluable data and samples
PET data used in the analysis consisted of 24 baseline
(pre-dose) scans (13 for the GSK1521498 group and 11
for the NTX group) and 44 post-dose scans (24
following GSK1521498 and 20 following NTX).
Evaluable fMRI data from 17 participants (9 scanned
following GSK1521498 and 8 scanned following
NTX) were included in the analysis. The treatment
groups of participants with evaluable PET or fMRI
data were well matched in terms of: age, body mass
index, scores on the TFEQ-R18 (ref. 47) and BIS-11
(ref. 48) questionnaires of eating behaviour and
impulsivity, the self-rated ‘liking’ of their preferred
palatable drink stimulus at baseline, dose of radio-
activity and injected mass of carfentanil during the
PET scans (Supplementary Table S1). Neither treat-
ment group demonstrated a significant post-dose
reduction in the ‘liking’ score for the palatable food
stimuli (Supplementary Table S1).
Pharmacokinetics
Plasma exposure parameters are summarised in
Table 1 for GSK1521498, NTX and 6-b-NTX. Represen-
tative concentration-time profiles for GSK1521498,
NTX and 6-b-NTX administered in this study are
shown in Supplementary Figure S1.
[11C]-carfentanil PET data
At baseline, [11C]-carfentanil showed high binding in
the striatum, the thalamus and the amygdala (Figure
1). Dose-dependent reductions in regional BPND were
observed following the administration of both
GSK1521498 and NTX in all ROIs except the occipital
cortex, justifying its selection as a reference region
(Figure 1).
There were no regional differences in RO for either
drug, so regional occupancies were averaged to
estimate global RO. Equation (3) provided a good fit
to the data on plasma concentration and RO acquired
at all times following a dose of GSK1521498, indicat-
ing a direct relationship between exposure and
occupancy40,49 (Figure 2). We were thus able to
estimate the plasma concentration of GSK1521498
associated with 50% occupancy of the m-OR:
EC50 = 7.10ngml
1 (95% confidence interval
(CI) = 5.96–8.25ngml1). For NTX and 6-b-NTX, there
was a time-dependent effect (hysteresis) on the
exposure-occupancy relationship, that is, a given
plasma concentration resulted in greater occupancy
at later time points. Hence, the direct model did not
provide adequate characterisation of RO based on
plasma concentrations of NTX or 6-b-NTX (Figure 2)
and time-independent EC50 estimates could not be
determined for either species.
Because of the dependence of the NTX dose–
occupancy relationship on the time post dose, the
dose–occupancy relationships for NTX and
GSK1521498 were estimated using data acquired
<8h post dose. The dose required to achieve 50%
RO (effective dose 50) was estimated at 1.50mg (95%
CI=1.24–1.76mg) for GSK1521498. The apparent
effective dose 50 for NTX was 5.60mg (95%
CI=3.65–7.54mg; Figure 1).
fMRI data
Regional analysis confirmed the main effect of
the task with significant BOLD signal increases in
regions predicted to be activated by food rewards
(Figure 3). Whole-brain mapping demonstrated
widespread activation involving these ROIs (as well
as some other cortical and sub-cortical regions),
thus further justifying their previous selection
(Figure 3 and Supplementary Table S4 for anatomical
details).
We tested for modulation of food reward-related
activation by each drug in each ROI. A significant
treatment effect was found only for GSK1521498 and
only in the amygdala (t=5.9, d.f. = 8, P=0.0004;
Figure 3 and Supplementary Table S2). GSK1521498
attenuated amygdalar activation in response to pala-
table stimuli; this effect remained after covarying for
between-subject differences in baseline BOLD activa-
tion and opioid RO (t=3.1, d.f. = 12, P=0.0085;
Supplementary Table S3). The standardised effect
size of GSK1521498 on amygdalar activation (2.0;
95% CI 2.7 to 1.2) was greater than the corre-
sponding effect size of NTX (0.1; 95% CI 0.9 to
0.7); although the difference in effect sizes (0.6) was
not quite significantly different from 0 (95% CI, 0.04
to 1.3; P=0.062; see Supplementary Tables S2, S3 for
details).
Whole-brain mapping demonstrated attenuation of
food reward-related activation by GSK1521498 in
bilateral amygdala and ventral striatum, as well as
thalamus and lateral cortical regions (Figure 4 and
Supplementary Table S4 for anatomical details). A
similar analysis suggested that different anatomical
regions (including the insula and dorsal striatum)
were modulated by NTX (Figure 4 and Supplemen-
tary Table S4 for anatomical details). A direct
comparison between drugs showed that attenuation
of food-related activation by GSK1521498 was
greater than the effects of NTX in amygdala
and ventral striatum bilaterally, whereas effects of
NTX were greater than those of GSK1521498
primarily in the insula (Figure 4 and Supplementary
Table S4).
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Discussion
We have combined molecular (PET) and functional
(fMRI) neuroimaging techniques in an innovative
experimental medicine study comparing the human
pharmacology of two OR antagonists, NTX and
GSK1521498. We have differentiated the two mole-
cules based on both tissue PK and PD parameters. We
propose that this general approach to integrated
neuroimaging may provide a powerful new strategy
for early evaluation of the therapeutic potential of
new molecules.
Receptor occupancy
Both drugs dose dependently reduced the specific
binding of [11C]-carfentanil. GSK1521498 demon-
strated high affinity for the target, and the relation-
ship between its plasma concentration and m-OR
occupancy was time independent. This allowed a
simple direct relationship to be defined between
plasma concentration and m-OR binding for
GSK1521498, distinguishing it from NTX, which
demonstrated an indirect relationship between ex-
posure and occupancy.40,49 The indirect binding
relationship observed for NTX could have several
explanations. An oral dose of NTX undergoes rapid
and extensive metabolism in humans, producing
pharmacologically active metabolites, 6-b-NTX being
the predominant one. On the basis of plasma PK and
in vitro receptor affinities of 6-b-NTX (Table 1,
Supplementary Figure S1), it seems likely that a
substantial proportion of the target occupancy follow-
ing an oral dose of NTX represents binding by 6-b-
NTX. However, we have modelled the relationship
between 6-b-NTX plasma concentration and RO over
time, and found that this also exhibited an indirect
relationship. We cannot exclude the presence of other
active metabolites with a different plasma kinetic
profile from NTX, which could account for the
observed RO time course. Alternatively, NTX or 6-b-
NTX may have long residence times at the m-OR, or
either molecule may not diffuse passively across the
blood–brain barrier or may be compartmentalised in
the brain parenchyma. Any of these phenomena
could result in slow equilibration between the m-OR
and the plasma compartments.
Functional efficacy
The pharmacological fMRI data indicated that
GSK1521498 and NTX modulate different brain
regions showing significant fMRI activation responses
to palatable food stimuli. We did not find a significant
effect of NTX in any of the pre-specified ROIs,
whereas GSK1521498 was associated with significant
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Figure 2 Relationships between plasma concentration and
opioid receptor occupancy for (a) GSK1521498, (b) naltrex-
one and (c) 6-b-naltrexol. The timing of individual scans
after administration of GSK1521498 or naltrexone is
indicated by the shape of the point markers. For
GSK1521498, the relationship between plasma exposure
and receptor occupancy is independent of time and well
fitted by equation (3); the vertical line indicates the effective
concentration 50 (EC50) and the dotted lines its 95%
confidence interval. For naltrexone and 6–b-naltrexol, at a
given plasma concentration, receptor occupancy is greater
for later scans; this hysteresis is highlighted by the arrow
which indicates the time ordering of scans.
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attenuation of food-related activation in the amygda-
la. Whole-brain mapping showed that effects of
GSK1521498 were significantly greater on activation
in the amygdala and ventral striatum, whereas any
effects of NTX were greatest in the insular region.
Previous fMRI studies have shown that BOLD activa-
tion in the amygdala and ventral striatum can be
related to incentive salience and to behaviours
reinforced by food or other rewards.39 The functional
role of the insula is more complex, but it is known
to play a role in interoceptive and gustatory
processing.50,51
Multiple factors could be responsible for pharma-
codynamic differences between GSK1521498 and
NTX. GSK1521498 has considerably greater selectiv-
ity for the m-OR over the k-OR than either NTX or 6-b-
NTX (Table 1). Pre-clinical studies have indicated
that k-OR and m-OR signalling may have different
effects on feeding52,53 and reward. Agonism at m-ORs
facilitates dopaminergic neurotransmission in
the ventral striatum, which has been specifically
implicated in food reward processing. On the other
hand, k-OR agonism tends to reduce dopamine
release in the ventral striatum.54,55 The reported
selectivity of NTX and 6-b-NTX (Table 1) implies k-
OR occupancy in the range of 50–80% at doses which
produce 80–90% occupancy of the m-OR, making
interactions between the two receptor systems rele-
vant for the mode of action of NTX. It may also be
relevant that GSK1521498, similar to NTX, can
behave as a neutral antagonist or inverse agonist,
depending on levels of constitutive activity, whereas
6-b-NTX behaves consistently as a neutral antago-
nist.29,56
Methodological issues
A key strength of the study design is that the PET and
fMRI data were acquired from the same participants
in the same scanning sessions. This imposed the
constraint that the first fMRI scan was always
acquired pre-dose and the second scan was acquired
post dose, allowing the potential for task repetition
Figure 3 Brain activation by a palatable food stimulus, and the effects of GSK1521498 and naltrexone on food reward-
related activation in selected regions of interest. (a) Whole-brain map of brain regions activated by experimental contrast
between palatable food stimulus and purified water; z indicates distance (mm) superior or inferior to the inter-commissural
plane in standard stereotactic space. (b) Bar chart showing magnitude of blood oxygenation level-dependent (BOLD)
activation by palatable stimuli versus purified water in nine pre-specified regions of interests: amygdala (AMG), caudate
(CAU), globus pallidus (GLP), hippocampus (HIP), insula (INS), nucleus accumbens (NAC), orbitofrontal cortex (OFC),
putamen (PUT) and thalamus (THA). (c) Bar chart showing magnitude of change in food-related activation, D-BOLD,
following treatment with GSK1521498 or naltrexone (NTX) in the same nine regions of interest. (d) Plots of BOLD activation
by palatable stimuli versus receptor occupancy from pre- and post-dose scans for each participant in each of the treatment
groups. Asterisks (*) denote effects that are significantly different from 0 at P<0.05 (Bonferroni corrected). MOR, mu opioid
receptor.
Pharmacological differentiation of opioid receptor antagonists
EA Rabiner et al
832
Molecular Psychiatry
effects on D-BOLD to confound effects of drug
treatment. The post hoc analysis of the regional fMRI
data demonstrated that greater D-BOLD was often
associated with greater baseline activation (Supple-
mentary Figure S2). Thus, we cannot entirely exclude
the possibility that the treatment difference in fMRI
markers may be partly attributable to the interaction
between a scanning order effect and sampling varia-
tion in baseline activation. However, the effect of
GSK1521498 on amygdala activation remains signifi-
cant after controlling for individual differences in
baseline activation.
We chose to activate food reward systems directly
by oral administration of a palatable stimulus, rather
than by visual presentation of food images, to
strengthen the translational link from the experimen-
tal data to potentially therapeutic effects of
GSK1521498 on food consumption. Because of the
radiation risks and costs of PET, the sample size was
modest and conferred limited statistical power to
detect treatment effects on fMRI measures. Finally,
the sample comprised exclusively adult males with
normal body weight, body mass index and eating
behaviours. OR signalling may differ between sexes,
Figure 4 Whole-brain mapping of treatment-related decreases in brain activation by food rewards. (a) Maps of significant
change in blood oxygenation level-dependent signal (D-BOLD) in the naltrexone (NTX)-treated group (green voxels) or in the
GSK1521498-treated group (red voxels). (b) Map of significant differences in D-BOLD between treatment groups:
D-BOLDGSK1521498 >D-BOLDNTX (yellow voxels) or D-BOLDNTX>D-BOLDGSK1521498 (green voxels). z indicates distance (mm)
superior or inferior to the inter-commissural plane in standard stereotactic space.
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and in relation to obesity and eating behaviours,57 so
our results should be generalised judiciously.
Therapeutic implications
Drugs that attenuate m-OR signalling are theoretically
likely to be beneficial across a range of disorders of
compulsive consumption, marked by habitual or
uncontrollable ingestion of food, alcohol, opiates or
stimulant drugs.27 The novel ligand GSK1521498 has
high selectivity for the m-OR in vitro and high affinity
for ORs in vivo. Compared with NTX, we have shown
that it has a direct relationship between m-OR
occupancy and plasma concentration, and clearer
evidence for functional efficacy in attenuating amyg-
dala activation by food rewards. We hypothesise that
these pharmacological differences may be associated
with differences in therapeutic efficacy. For example,
GSK1521498 may have greater efficacy than NTX in
the treatment of maladaptive reward-driven eating
behaviours, such as bingeing on energy-dense foods,
that are commonly associated with obesity.
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